Oral proprietary Chinese medicine for lupus nephritis: A bayesian network meta-analysis

Oral proprietary Chinese medicine for lupus nephritis: A bayesian network meta-analysis

Objective: To analyze the efficacy and safety of proprietary Chinese medicines for the treatment of Lupus Nephritis (LN) based on the reticulated meta analysis. The study aim to provide evidence-based evidence for the clinical treatment of LN. Methods: The studies related to the randomized controlle...

Full description

Bibliographic Details
Main Authors:	Aitao Lin, Zhiying Zhang, Xiaoyu Liu, Jinyu Wu
Format:	Article
Language:	English
Published:	Elsevier 2023-08-01
Series:	Heliyon
Subjects:	Lupus nephritis Proprietary Chinese medicine Network meta-analysis Randomized controlled trial Bayesian model
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405844023059194

Similar Items

Lupus nephritis : frontiers and challenges /
by: Sheashaa, Hussein A.
Published: (2010)

Tubulointerstitial lupus nephritis
by: Ala Ali, et al.
Published: (2013-01-01)

Proprietary Medicines Containing Bupleurum chinense DC. (Chaihu) for Depression: Network Meta-Analysis and Network Pharmacology Prediction
by: Qiao-feng Li, et al.
Published: (2022-04-01)

Hidden face of lupus nephritis exposed: Isolated tubulointerstitial lupus nephritis
by: Muhammed Mubarak
Published: (2013-01-01)

Astragalus-containing Chinese herbal medicine used with Western medicine for lupus nephritis: a systematic review and meta-analysis of randomized controlled trials
by: Jinjiao Li, et al.
Published: (2025-02-01)

Application of herbal traditional Chinese medicine in the treatment of lupus nephritis
by: Liu Liu, et al.
Published: (2022-11-01)

Biologicals for the treatment of lupus nephritis: a Bayesian network meta-regression analysis
by: Xi Liu, et al.
Published: (2024-08-01)

USE OF RITUXIMAB IN PATIENTS WITH LUPUS NEPHRITIS
by: Anna Vasilyevna Torgashina, et al.
Published: (2010-08-01)

Promising Experimental Treatments for Lupus Nephritis: Key Talking Points and Potential Opportunities
by: Neves A, et al.
Published: (2023-07-01)

Efficacy of tacrolimus plus glucocorticoid for lupus nephritis: a Meta-analysis
by: Yi-xi Xing, et al.
Published: (2024-09-01)

The Clinicopathological Study of Lupus Nephritis
by: Raouf Rahim Merza, et al.
Published: (2014-08-01)

Comparative Effectiveness of Rituximab and Common Induction Therapies for Lupus Nephritis: A Systematic Review and Network Meta-Analysis
by: Kang Li, et al.
Published: (2022-04-01)

Lupus Nephritis and Dysbiosis
by: Marta Monticolo, et al.
Published: (2023-04-01)

Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis
by: Han Zhang, et al.
Published: (2023-12-01)

Lupus Nephritis, the therapy and the role of Rituximab in resistant cases
by: Hussein A. Nasir, et al.
Published: (2014-01-01)

Current and Emerging Therapy on Lupus Nephritis
by: Lucky Aziza Bawazier
Published: (2018-01-01)

Non-histologic factors discriminating proliferative lupus nephritis from membranous lupus nephritis
by: Oh Chan Kwon, et al.
Published: (2020-06-01)

The Legal Regulation of the Proprietary Rights in the People’s Republic of China: Comparison with Russian Law
by: A. V. Medvedev
Published: (2011-03-01)

Diagnostic value of TWEAK for predicting active lupus nephritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis
by: Hao-Yang Ma, et al.
Published: (2021-01-01)

Clinical efficacy and safety of rituximab in lupus nephritis
by: Zhong Z, et al.
Published: (2019-03-01)

Lupus nephritis – modern aspects of diagnosis and therapy. Part I
by: S. K. Solovyev, et al.
Published: (2024-03-01)

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
by: Marlene Plüß, et al.
Published: (2022-11-01)

Sailing south from regulations to strategies: Macau as a promising gateway for the export of proprietary Chinese medicines to ASEAN countries
by: Dong-mei Xue, et al.
Published: (2025-02-01)

Lupus nephritis in the XXI century
by: Irina N. Bobkova, et al.
Published: (2022-08-01)

Management of refractory lupus nephritis: challenges and solutions
by: Yo JH, et al.
Published: (2019-07-01)

Immunophenotyping identifies distinct cellular signatures for systemic lupus erythematosus and lupus nephritis
by: Yi Tong V. Aw, et al.
Published: (2023-03-01)

Lupus Nephritis in Males: Clinical Features, Course, and Prognostic Factors for End-Stage Renal Disease
by: Andrés Urrestarazú, et al.
Published: (2017-09-01)

Urinary biomarkers associated with podocyte injury in lupus nephritis
by: Zhiying Guo, et al.
Published: (2024-01-01)

Expressions of IFN-γ and IL-4 before and after Treatment of Lupus Nephritis with Traditional Chinese Medicine Combined with Cyclophosphamide and Their Values for Efficacy Prediction and Evaluation
by: Yan JIANG, et al.
Published: (2020-05-01)

Management of Lupus Nephritis
by: Merkel F, et al.
Published: (2000-01-01)

Experience using low doses of calcineurin inhibitors in the treatment of refractory lupus nephritis
by: César Augusto Restrepo Valencia, et al.
Published: (2014-10-01)

Renalase and lupus nephritis: disease activity and histopathological classification
by: Marwa Y Mahgoub, et al.
Published: (2018-01-01)

Novel Therapeutics for Management of Lupus Nephritis: What Is Next?
by: Sayali B. Thakare, et al.
Published: (2023-08-01)

Evaluation of Treatment Response in Lupus Nephritis
by: Anca BOBIRCA, et al.
Published: (2021-12-01)

Lupus nephritis. Part II, modern ideas about therapy
by: Elena A. Aseeva, et al.
Published: (2024-09-01)

Tim-1 alleviates lupus nephritis-induced podocyte injury via regulating autophagy
by: Yunxia Yu, et al.
Published: (2021-10-01)

Lupus Nephritis, Pauci Immune Rapidly Progressive Glomerolu Nephritis: Case Report
by: Naser Saeidi, et al.
Published: (2018-02-01)

Biomarkers in biological fluids and their potential use as indicators of lupus nephritis in individuals with systemic lupus erythematous
by: Lisandro Pacheco-Lugo, et al.
Published: (2014-05-01)

Histopathological study of lupus nephritis with special reference to nonlupus nephritis, focal segmental glomerulosclerosis, interstitial nephritis, and amyloidosis
by: Usha Singh, et al.
Published: (2016-01-01)

Lupus nephritis in Bangladesh: unfolding the story
by: Mubarak Muhammed
Published: (2016-01-01)